<DOC>
	<DOCNO>NCT00959114</DOCNO>
	<brief_summary>A phase 2a study evaluate safety efficacy ALV003 treat celiac disease .</brief_summary>
	<brief_title>Safety Efficacy ALV003 Treatment Celiac Disease</brief_title>
	<detailed_description>Double-blind , placebo control study efficacy , safety tolerability 6-weeks treatment ALV003 patient well-controlled celiac disease . Approximately 110 biopsy proven celiac disease patient randomize treatment ALV003 placebo 1:1 ratio . Patients require pre-dose post-treatment intestinal biopsy , also require ingest foodstuff contains specify amount gluten active phase study along study treatment . Patients return clinic weekly first two week , every two week thereafter safety visit . Patients return clinic 28 day completion treatment final safety follow-up . Safety closely monitor throughout study include laboratory parameter clinical assessment adverse event .</detailed_description>
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>History biopsyproven celiac disease Adherence glutenfree diet TG2 antibody negative Signed inform consent Active dermatitis herpetiformis History IgEmediated reaction gluten Use specific medication 6 month prior entry History alcohol abuse illicit drug use Current untreated GI disease Positive pregnancy test Received experimental drug within 14 day randomization Uncontrolled chronic disease condition Uncontrolled complication celiac disease Any medical condition , could adversely affect participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Celiac Disease</keyword>
	<keyword>Coeliac Disease</keyword>
	<keyword>Celiac Sprue</keyword>
	<keyword>Keliakia</keyword>
</DOC>